Literature DB >> 20380581

The auto-antigen repertoire in myasthenia gravis.

Kathleen Vrolix1, Judith Fraussen, Peter C Molenaar, Mario Losen, Veerle Somers, Piet Stinissen, Marc H De Baets, Pilar Martínez-Martínez.   

Abstract

Myasthenia Gravis (MG) is an antibody-mediated autoimmune disorder affecting the postsynaptic membrane of the neuromuscular junction (NMJ). MG is characterized by an impaired signal transmission between the motor neuron and the skeletal muscle cell, caused by auto-antibodies directed against NMJ proteins. The auto-antibodies target the nicotinic acetylcholine receptor (nAChR) in about 90% of MG patients. In approximately 5% of MG patients, the muscle specific kinase (MuSK) is the auto-antigen. In the remaining 5% of MG patients, however, antibodies against the nAChR or MuSK are not detectable (idiopathic MG, iMG). Although only the anti-nAChR and anti-MuSK auto-antibodies have been demonstrated to be pathogenic, several other antibodies recognizing self-antigens can also be found in MG patients. Various auto-antibodies associated with thymic abnormalities have been reported, as well as many non-MG-specific auto-antibodies. However, their contribution to the cause, pathology and severity of the disease is still poorly understood. Here, we comprehensively review the reported auto-antibodies in MG patients and discuss their role in the pathology of this autoimmune disease.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20380581     DOI: 10.3109/08916930903518073

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  14 in total

1.  The trouble with Tribbles: do antibodies against TRIB2 cause narcolepsy?

Authors:  Andrew S P Lim; Thomas E Scammell
Journal:  Sleep       Date:  2010-07       Impact factor: 5.849

2.  Myasthenogenicity of the main immunogenic region and endogenous muscle nicotinic acetylcholine receptors.

Authors:  Jie Luo; Jon Lindstrom
Journal:  Autoimmunity       Date:  2011-10-21       Impact factor: 2.815

3.  Preconditioned mesenchymal stem cells treat myasthenia gravis in a humanized preclinical model.

Authors:  Muriel Sudres; Marie Maurer; Marieke Robinet; Jacky Bismuth; Frédérique Truffault; Diane Girard; Nadine Dragin; Mohamed Attia; Elie Fadel; Nicola Santelmo; Camille Sicsic; Talma Brenner; Sonia Berrih-Aknin
Journal:  JCI Insight       Date:  2017-04-06

Review 4.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

5.  Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis.

Authors:  Muthusamy Thiruppathi; Julie Rowin; Balaji Ganesh; Jian Rong Sheng; Bellur S Prabhakar; Matthew N Meriggioli
Journal:  Clin Immunol       Date:  2012-10-07       Impact factor: 3.969

6.  Clinical and serologic parallels to APS-I in patients with thymomas and autoantigen transcripts in their tumors.

Authors:  Anette S B Wolff; Jaanika Kärner; Jone F Owe; Bergithe E V Oftedal; Nils Erik Gilhus; Martina M Erichsen; Olle Kämpe; Anthony Meager; Pärt Peterson; Kai Kisand; Nick Willcox; Eystein S Husebye
Journal:  J Immunol       Date:  2014-09-17       Impact factor: 5.422

Review 7.  Bortezomib: a proteasome inhibitor for the treatment of autoimmune diseases.

Authors:  Naeemeh Khalesi; Shahla Korani; Mitra Korani; Thomas P Johnston; Amirhossein Sahebkar
Journal:  Inflammopharmacology       Date:  2021-08-23       Impact factor: 4.473

8.  Immunoglobulin analysis tool: a novel tool for the analysis of human and mouse heavy and light chain transcripts.

Authors:  Tobias Rogosch; Sebastian Kerzel; Kam Hon Hoi; Zhixin Zhang; Rolf F Maier; Gregory C Ippolito; Michael Zemlin
Journal:  Front Immunol       Date:  2012-06-28       Impact factor: 7.561

Review 9.  An introduction to biomaterial-based strategies for curbing autoimmunity.

Authors:  Jamal S Lewis; Riley P Allen
Journal:  Exp Biol Med (Maywood)       Date:  2016-05

10.  Myasthenia gravis: analysis of serum autoantibody reactivities to 1827 potential human autoantigens by protein macroarrays.

Authors:  Anne Becker; Nicole Ludwig; Andreas Keller; Björn Tackenberg; Christian Eienbröker; Wolfgang H Oertel; Klaus Fassbender; Eckart Meese; Klemens Ruprecht
Journal:  PLoS One       Date:  2013-03-04       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.